Materials and methods relating to the diagnosis and treatment of diabetes and obesity
AssigneeRodaris Pharmaceuticals Limited
InventorsThomas William Rademacher, Patricia McLean
Life of this patent
Estimating the term…
Abstract
The diagnosis of diabetes based on the level or ratio of P- and A-type inositolphosphoglycans (IPGs) in a sample from a patient, and the use of P- and A-type IPGs or their antagonists in the treatment of diabetes is disclosed. In particular, the present invention provides treatment of IDDM or lean type II diabetes (NIDDM) with a mixture of P- and A-type mediators, and treatment of obese type II diabetes (NIDDM) with a P-type mediator and/or an A-type antagonist.
Claims19
A method of diagnosing diabetes, the method comprising determining the level or ratio of P- and/or A-type inositolphosphoglycans (IPGs) in a biological sample from a patient.
Use of P- or A-type inositolphosphoglycans (IPGs), or antagonists to P- or A-type IPGs, in the preparation of a medicament for the treatment of diabetes.
Use of a P-type IPG arid/or an A-type IPG antagonist in the preparation of a medicament for the treatment of obese type II diabetes.
Use of a mixture of P-type and A-type IPGs in the preparation of a medicament for the treatment of IDDM or lean type II diabetes (NIDDM).
A pharmaceutical composition comprising a P-type IPG and/or an A-type IPG antagonist in combination with a pharmaceutically acceptable carrier.
A pharmaceutical composition comprising a mixture of P- and A-type IPGs in combination with a pharmaceutically acceptable carrier.
A method of screening for P- or A-type IPG antagonists, the method comprising:
- (a) contacting a candidate antagonist and a P- or A-type IPG in an assay for a biological property of the P- or A-type IPG under conditions in which the IPG and the candidate antagonist can compete;
- (b) measuring the biological property of the IPG;
- and,
- (c) selecting candidate antagonists which reduce the biological activity of the IPG.
Dependencies are inferred from the claim text.